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Introduction
With the increased number of cancer patients throughout the world, the usage ratio of opioidderived analgesics during treatment periods or for control of the cancer pain has also increased. Unfortunately, opioid usage is limited because of the pain it induces. In 1880, Rossbach concluded that 'opioid addiction is a disease itself ', considering the opioid effects such as "hyperesthesia and anger" among other disadvantages of chronic opioid consumption. [1, 2] It was later proven by laboratory and clinical reports that the pain threshold decreased and the incidence of increased atypical pain rose with long-term opioid consumption. Thereafter, efforts have been made to understand the mechanism of opioid-induced hyperalgesia (OIH) in order to prescribe more effective pain medications.
There are five mechanisms suggested to play a role in OIH development. The theories coming into prominence include spinal dynorphins, facilitation, genetics, decreased re-uptake, and retention of the central glutaminergic system. [2] In terms of clinical practice, it has been thought that the location of effect of medications was the mu receptor; however, it has been shown that the medications may be effective via delta, kappa or sigma receptors as the mechanism of action or the supporting mechanism of action, and it has been considered that those could be effective as well. [3] The medications recommended for OIH treatment include ketamine, methadone, dextromethorphan, COX-2 inhibitors, and α-2 receptor agonists. [4, 5] Clonidine, an α2-adrenoceptor agonist, has been shown to be an effective adjunct to clinical anesthesia and pain management in addition to being an antihypertensive agent. There are findings that have highlighted the antinociceptive effects of intrathecal administration of clonidine in animal models of pain. [6] We discuss herein our experience with a cancer patient treated for OIH with intrathecal clonidine, as well as the relevant literature.
Case Report
A 40-year-old male patient 45 kg weighing had been diagnosed with stage IV colon cancer 2.5 years ago and underwent a Whipple operation. He had used non-steroidal anti-inflammatory drugs (NSAIDs), opioid analgesics and steroid preparations casually for his increased pain without any monitoring for a year. The analgesics used were dexketoprofen trometamol (Arveles®) tablet 2x1 regularly for 1 year and 12.5, 25, 50, and 100 mcg transdermal fentanyl (Duragesic®) (TDF) patches monthly. There was also a history of 1x1 100 mg tramadol hydrochloride (Contramal®) for 6 months. When he first applied to our clinic, bilateral median branch lesion radiofrequency thermocoagulation (RFT) at the L2-5 level was administered for his complaint of mechanical lumbar pain, considering facet syndrome. His pain reduced and he was discharged with a prescription of pregabalin 150 mg/daily and tramadol 100 mg/ daily. First 100 then 150-200 mcg TDF was added to the treatment after three weeks when he started to suffer abdominal visceral pain. Two weeks later, the patient was operated under combined spinoepidural anesthesia for abscess in the liver and peritonea. When the patient with severe abdominal, pubic, and rectal pain (visual analogue scale [VAS] 8) unresponsive to epidural analgesic (10 mg morphine + bupivacaine %0.25/5 mL/daily) presented to the algology clinic 4 days after the operation, he was sleep-deprived, restless and in a panic state. Intrathecal 1 mg morphine was applied through the L4-5 space. The patient exhibited increasing pain (VAS 9) after the intervention and was admitted to the clinic, and dexketoprofen (Arveles®) and diazem were applied, but the complaints persisted. Intravenous (IV) bolus dexmedetomidine (1 µg/ kg) was given considering these findings supporting an OIH diagnosis. Dexmedetomidine infusion (0.2 µg/kg/h) was administered, and his complaints began to recover (VAS 4); he was placed under close observation in the reanimation unit. Totally, 4 units of erythrocyte suspension and 2 units of fresh frozen plasma infusion were given to the patient, with hemoglobin (Hb) of 5.7 in routine tests. The patient slept, relaxed and could communicate more calmly with the people around him. Subcutaneous (SC) ketamine (10 mg) and morphine (2 mg) daily were applied. His pain was partially controlled with dexmedetomidine, and his VAS remained at 4. Four days later, intrathecal clonidine (30 µg) was administered to the patient, and after he relaxed (VAS 1-2) for 30 minutes, an intrathecal port was placed at the L4-5 level. Both cancer pain and OIH were controlled and treated with intrathecal clonidine (90 µg/day) for 18 days until his death.
Discussion
Opioid analgesics have been used in cancer and non-cancer chronic pain for years and their usage is increasing. [1] [2] [3] [4] Hyperalgesia induced by opioid usage was defined in the 19th century. In 1870, Albutt [7] observed that in patients being treated with morphine, the morphine itself could cause more pain, and he suggested it should be used cautiously. In 1880, Rossbach specified that clinical findings such as restlessness, sleeping disorder, hyperesthesia, and neuralgia were seen in OIH. [8] In the 21st century, the studies concerning OIH have focused on the effects of the opioids' toxic metabolites, such as morphine-3-glucuronide, on the central nervous system. [9] However, a consensus has not been achieved in these studies.
It can be helpful to reduce the dose if the pain does not relax during high-dose opioid consumption. Vorobeychik et al. [10] reported a case in which pain was detected in the lower thoracic vertebra and thorax (VAS 8/10) in a 56-year-old male patient with squamous cell lung cancer and spinal metastasis. He received oxycodone, morphine and hydromorphone. As the patient's pain persisted, opioid doses were reduced and methadone was started, and the pain level was reduced to 3/10.
Ketamine acts as an N-methyl-d-aspartic acid (NMDA) receptor antagonist, and it has been shown in several studies that preoperative ketamine usage reduces the opioid consumption. [11] Again, it has been noted that ketamine usage in cancer patients reduces the opioid consumption and can be used in OIH treatment. [9, 11] Methadone is actually a weak NMDA antagonist, and it reduces the dose of opioid consumption. It has been reported in studies that methadone usage in rotation with opioids decreases the possibility of OIH. [12, 13] However, clinical situations such as tardive kinesia, complex conversion and toxicity, which may be related to methadone usage, limit the methadone consumption. [13] Dextromethorphan can also be used as an NMDA receptor antagonist to decrease the possibility of OIH development or, if it develops, to treat it. Galer et al. [14] conducted three randomized large studies on dextromethorphan and OIH, and suggested a treatment regimen they designated as MorphiDex, in which both opioid/NMDA are used.
Koppert et al. [15] showed that clonidine, which is an α-2 agonist, was effective in the treatment of OIH. Quartilho et al. [16] observed that clonidine applied even in one dose was effective on the reduction of side effects related to opioid usage. These results led us to consider whether α-2 receptors may play a role in development of the side effects of opioids. [15, 16] Data of a previous study showed that a single intrathecal administration of clonidine could dose-dependently attenuate the existing behavioral hyperalgesia. As a previous study suggested that perineural clonidine injection after partial sciatic nerve ligation (PSNL) injury could delay the development of hypersensitivity, [17] the results of Feng's study [6] might further indicate the therapeutic effects of clonidine on neuropathic pain. The results of de Kock's study [18] were that spinal clonidine, in addition to a transitory analgesic effect, possesses anti-hyperalgesic properties resulting in a reduction in the area of secondary hyperalgesia around the wound and a reduction in residual pain for up to 6 months in the postoperative period. In that study, the intrathecal administration of 300 µg of clonidine was not associated with serious side effects. Particularly, no postoperative oversedation was recorded. The only noticeable problem was the increased incidence of intraoperative moderate hypotensive events.
In the presented case, we first used NSAID medication and SC low-dose morphine upon suspicion of OIH development. The patient did not relax sufficiently, and the positive response to dexmedetomidine bolus, which is an α-2 agonist, and infusion showed the α-2 receptor sensitivity. Both OIH and cancer pain in this patient were treated with intrathecal clonidine. Due to the limited oral intake of the patient and an adaptation problem, intrathecal application was preferred primarily. In conclusion, intrathecal clonidine administration Pain management with intrathecal clonidine in a colon cancer patient with opioid hyperalgesia
